A psoriasis med, which seems like bad news since sometimes they end up working for RA.
From Fierce Pharma:
http://www.fiercepharma.com/story/emea-raptiva-pml-risks-outweigh-benefits/2009-02-20?utm_medium=rss&utm_source=rss&cmp-id=OTC-RSS-FP0
"In announcing this case--the third confirmed diagnosis reported in
recent months--the EMEA recommended suspending the drug in the E.U.,
saying its benefits no longer outweigh the risks.
The FDA didn't go so far. In October, when a previous PML case was
announced, the agency added a "black box" warning to Raptiva's label;
this time around, the FDA cautioned patients and doctors to be on the
lookout for PML symptoms."
Copyright ArthritisInsight.com